Results 81 to 90 of about 12,392,515 (266)

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia

Patient Preference and Adherence, 2015
Roberto Furlan,1 Sangeeta Krishnan,2 Jeffrey Vietri3 1Advanced Methods, Kantar Health, Epsom, Surrey, UK; 2Global Health Economics and Outcomes Research, Biogen, MA, USA; 3Health Outcomes, Kantar Health, Milan, Italy Introduction: New longer-acting ...
Furlan R, Krishnan S, Vietri J
doaj  

A study to determine the prevalence, clinical profile and incidence of formation of inhibitors in patients of hemophilia in north eastern part of India

Journal of Family Medicine and Primary Care, 2019
Introduction: Deficiency of factor VIII (Hemophilia A), factor IX (Hemophilia B) and Von Willebrand's factor are the most frequent coagulation defects.
Sandip Kumar, Sachidanand Sinha, Anju Bharti, Lalit P Meena, Vineeta Gupta, Jyoti Shukla   +5 more
doaj   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

GlycoPEGylated recombinant factor IX for hemophilia B in context

, 2018
Elena Santagostino, Maria Elisa Mancuso Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca’ Granda Foundation, Maggiore Hospital Policlinic, Milan, Italy Abstract: Decisions over hemophilia treatment selection and switching involve ...
Santagostino E, Mancuso ME
core  

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Hemophilia, HIV and AIDS : perspectives in living : workshop study guide / John (Jack) R. McDonald, Jonathan Cooper

, 1991
Prepared by the World Federation of Hemophilia in collaboration with the World Health Organization79 ...
World Health Organization, Copper, Jonathan, McDonald, John R, World Federation of Hemophilia   +3 more
core  

Establishing the prevalence and prevalence at birth of hemophilia in males : a meta-analytic approach using national registries

, 2019
Background: The large observed variability in hemophilia prevalence prevents robust estimation of burden of disease. Objective: To estimate the prevalence and prevalence at birth of hemophilia and the associated life expectancy disadvantage ...
Chambost, H., Stonebraker, Jeffrey, Makris, Michael, Makris, M., Germini, F., Coffin, D., Germini, Federico, Herr, C., Stonebraker, J.S., Coffin, Donna, Chambost, Hervé, Iorio, A., Iorio, Alfonso, Herr, Christine   +13 more
core   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Spectrum of hemophilia in Diyala-Iraq

Diyala Journal of Medicine, 2019
Background: Deficiencies of coagulation factors have been recognized for centuries. The most common inherited factor deficiencies are the hemophilias, X-linked diseases caused by deficiency of factor VIII (hemophilia A) or factor IX ( hemophilia B ...
Imad Ahmed Lateef, Hayder Jassim Hamood, Hayder Jassim Hamood, Oday Abbood Khaleel   +3 more
doaj   +2 more sources

Clinical observations of hemophilia [PDF]

, 1970
application/pdfClinical and laboratory studies were established on 7 cases with hemophilia A and 2 cases with hemophilia B. 1) The age of the patients in the first visit to our clinic were less than 5 years old, except for one case.
ヨシオカ, ケイイチロウ, キタ, エツコ, 喜多, 悦子, 北脇, 達雄, 吉岡, 慶一郎, フロウチ, タケシ, FUROUCHI, Takashi, 川原, 浩二, カワハラ, コウジ, イリエ, アキコ, 尼川, 佳江, IRIE, Akiko, 風呂内, 充, 入江, 章子, キタワキ, タツオ, YOSHIOKA, Keiichiro, KAWAHARA, Koji, KITA, Etsuko, アマカワ, ヨシエ, KITAWAKI, Tatsuo, AMAKAWA, Yoshie   +20 more
core   +2 more sources